Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse

Autor: Suzana Mittelstadt, Olga Kelemen, Jakob Admard, Axel Gschwind, André Koch, Sarah Wörz, Ernst Oberlechner, Tobias Engler, Irina Bonzheim, Annette Staebler, Nicola Weidner, Frank Stubenrauch, Thomas Iftner, Olaf Riess, Christopher Schroeder, Stefan Kommoss, Stephan Ossowski
Rok vydání: 2023
Předmět:
Zdroj: British Journal of Cancer. 128:2097-2103
ISSN: 1532-1827
0007-0920
DOI: 10.1038/s41416-023-02233-x
Popis: Background HPV-related cervical cancer (CC) is the fourth most frequent cancer in women worldwide. Cell-free tumour DNA is a potent biomarker to detect treatment response, residual disease, and relapse. We investigated the potential use of cell-free circulating HPV-DNA (cfHPV-DNA) in plasma of patients with CC. Methods cfHPV-DNA levels were measured using a highly sensitive next-generation sequencing-based approach targeting a panel of 13 high-risk HPV types. Results Sequencing was performed in 69 blood samples collected from 35 patients, of which 26 were treatment-naive when the first liquid biopsy sample was retrieved. cfHPV-DNA was successfully detected in 22/26 (85%) cases. A significant correlation between tumour burden and cfHPV-DNA levels was observed: cfHPV-DNA was detectable in all treatment-naive patients with advanced-stage disease (17/17, FIGO IB3–IVB) and in 5/9 patients with early-stage disease (FIGO IA–IB2). Sequential samples revealed a decrease of cfHPV-DNA levels in 7 patients corresponding treatment response and an increase in a patient with relapse. Conclusions In this proof-of-concept study we demonstrated the potential of cfHPV-DNA as a biomarker for therapy monitoring in patients with primary and recurrent CC. Our findings facilitate the development of a sensitive and precise, non-invasive, inexpensive, and easily accessible tool in CC diagnosis, therapy monitoring and follow-up.
Databáze: OpenAIRE
Externí odkaz: